-
Je něco špatně v tomto záznamu ?
Vitamin D receptor regulates TGF-β signalling in systemic sclerosis
P. Zerr, S. Vollath, K. Palumbo-Zerr, M. Tomcik, J. Huang, A. Distler, C. Beyer, C. Dees, K. Gela, O. Distler, G. Schett, JH. Distler,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Health & Medicine (ProQuest) od 1939-01-01 do Před 6 měsíci
Family Health Database (ProQuest) od 1939-01-01 do Před 6 měsíci
Odkazy
PubMed
24448349
DOI
10.1136/annrheumdis-2013-204378
Knihovny.cz E-zdroje
- MeSH
- bleomycin toxicita MeSH
- dospělí MeSH
- ergokalciferoly farmakologie MeSH
- fibroblasty účinky léků metabolismus MeSH
- fibróza chemicky indukované metabolismus MeSH
- kůže účinky léků metabolismus patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- malá interferující RNA metabolismus MeSH
- mladý dospělý MeSH
- modely nemocí na zvířatech MeSH
- myši MeSH
- proteiny Smad účinky léků metabolismus MeSH
- receptory kalcitriolu agonisté metabolismus MeSH
- senioři MeSH
- signální transdukce účinky léků fyziologie MeSH
- systémová sklerodermie metabolismus MeSH
- transformující růstový faktor beta účinky léků metabolismus MeSH
- zvířata MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- myši MeSH
- senioři MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Vitamin D receptor (VDR) is a member of the nuclear receptor superfamily. Its ligand, 1,25-(OH)2D, is a metabolically active hormone derived from vitamin D3. The levels of vitamin D3 are decreased in patients with systemic sclerosis (SSc). Here, we aimed to analyse the role of VDR signalling in fibrosis. METHODS: VDR expression was analysed in SSc skin, experimental fibrosis and human fibroblasts. VDR signalling was modulated by siRNA and with the selective agonist paricalcitol. The effects of VDR on Smad signalling were analysed by reporter assays, target gene analyses and coimmunoprecipitation. The effects of paricalcitol were evaluated in the models of bleomycin-induced fibrosis and fibrosis induced by overexpression of a constitutively active transforming growth factor-β (TGF-β) receptor I (TBRI(CA)). RESULTS: VDR expression was decreased in fibroblasts of SSc patients and murine models of SSc in a TGF-β-dependent manner. Knockdown of VDR enhanced the sensitivity of fibroblasts towards TGF-β. In contrast, activation of VDR by paricalcitol reduced the stimulatory effects of TGF-β on fibroblasts and inhibited collagen release and myofibroblast differentiation. Paricalcitol stimulated the formation of complexes between VDR and phosphorylated Smad3 in fibroblasts to inhibit Smad-dependent transcription. Preventive and therapeutic treatment with paricalcitol exerted potent antifibrotic effects and ameliorated bleomycin- as well as TBRI(CA)-induced fibrosis. CONCLUSIONS: We characterise VDR as a negative regulator of TGF-β/Smad signalling. Impaired VDR signalling with reduced expression of VDR and decreased levels of its ligand may thus contribute to hyperactive TGF-β signalling and aberrant fibroblast activation in SSc.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15023591
- 003
- CZ-PrNML
- 005
- 20150727102807.0
- 007
- ta
- 008
- 150709s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/annrheumdis-2013-204378 $2 doi
- 035 __
- $a (PubMed)24448349
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Zerr, Pawel $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
- 245 10
- $a Vitamin D receptor regulates TGF-β signalling in systemic sclerosis / $c P. Zerr, S. Vollath, K. Palumbo-Zerr, M. Tomcik, J. Huang, A. Distler, C. Beyer, C. Dees, K. Gela, O. Distler, G. Schett, JH. Distler,
- 520 9_
- $a BACKGROUND: Vitamin D receptor (VDR) is a member of the nuclear receptor superfamily. Its ligand, 1,25-(OH)2D, is a metabolically active hormone derived from vitamin D3. The levels of vitamin D3 are decreased in patients with systemic sclerosis (SSc). Here, we aimed to analyse the role of VDR signalling in fibrosis. METHODS: VDR expression was analysed in SSc skin, experimental fibrosis and human fibroblasts. VDR signalling was modulated by siRNA and with the selective agonist paricalcitol. The effects of VDR on Smad signalling were analysed by reporter assays, target gene analyses and coimmunoprecipitation. The effects of paricalcitol were evaluated in the models of bleomycin-induced fibrosis and fibrosis induced by overexpression of a constitutively active transforming growth factor-β (TGF-β) receptor I (TBRI(CA)). RESULTS: VDR expression was decreased in fibroblasts of SSc patients and murine models of SSc in a TGF-β-dependent manner. Knockdown of VDR enhanced the sensitivity of fibroblasts towards TGF-β. In contrast, activation of VDR by paricalcitol reduced the stimulatory effects of TGF-β on fibroblasts and inhibited collagen release and myofibroblast differentiation. Paricalcitol stimulated the formation of complexes between VDR and phosphorylated Smad3 in fibroblasts to inhibit Smad-dependent transcription. Preventive and therapeutic treatment with paricalcitol exerted potent antifibrotic effects and ameliorated bleomycin- as well as TBRI(CA)-induced fibrosis. CONCLUSIONS: We characterise VDR as a negative regulator of TGF-β/Smad signalling. Impaired VDR signalling with reduced expression of VDR and decreased levels of its ligand may thus contribute to hyperactive TGF-β signalling and aberrant fibroblast activation in SSc.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a bleomycin $x toxicita $7 D001761
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a ergokalciferoly $x farmakologie $7 D004872
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fibroblasty $x účinky léků $x metabolismus $7 D005347
- 650 _2
- $a fibróza $x chemicky indukované $x metabolismus $7 D005355
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a malá interferující RNA $x metabolismus $7 D034741
- 650 _2
- $a receptory kalcitriolu $x agonisté $x metabolismus $7 D018167
- 650 _2
- $a systémová sklerodermie $x metabolismus $7 D012595
- 650 _2
- $a signální transdukce $x účinky léků $x fyziologie $7 D015398
- 650 _2
- $a kůže $x účinky léků $x metabolismus $x patologie $7 D012867
- 650 _2
- $a proteiny Smad $x účinky léků $x metabolismus $7 D051785
- 650 _2
- $a transformující růstový faktor beta $x účinky léků $x metabolismus $7 D016212
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vollath, Stefan $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
- 700 1_
- $a Palumbo-Zerr, Katrin $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
- 700 1_
- $a Tomcik, Michal $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany Department of Rheumatology of the First Faculty of Medicine, Institute of Rheumatology, Charles University, Prague, Czech Republic.
- 700 1_
- $a Huang, Jingang $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
- 700 1_
- $a Distler, Alfiya $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
- 700 1_
- $a Beyer, Christian $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
- 700 1_
- $a Dees, Clara $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
- 700 1_
- $a Gela, Kolja $u Department of Orthopedic Trauma Surgery, University of Erlangen-Nuremberg, Erlangen, Germany.
- 700 1_
- $a Distler, Oliver $u Center of Experimental Rheumatology and Zurich Center of Integrative Human Physiology, University Hospital Zurich, Zurich, Switzerland.
- 700 1_
- $a Schett, Georg $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
- 700 1_
- $a Distler, Jörg H W $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
- 773 0_
- $w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 74, č. 3 (2015), s. e20
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24448349 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20150727102851 $b ABA008
- 999 __
- $a ok $b bmc $g 1083928 $s 906584
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 74 $c 3 $d e20 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
- LZP __
- $a Pubmed-20150709